Heart & Cholesterol Stack

Best-in-class: Healthy Lipid Bundle

Thorne's lipid bundle, aimed at cholesterol and cardiovascular risk markers. Which products Thorne boxes into it is not stated on this page.

How Heart & Cholesterol Stack actually works

Combines the three non-overlapping lipid mechanisms — absorption blockade via plant sterols or fiber, synthesis modulation via bergamot or red yeast rice, and endothelial support via omega-3 and flavonoids. Because they act at different points they are genuinely additive rather than redundant.

Where to get Heart & Cholesterol Stack

The evidence for Heart & Cholesterol Stack

Graded by what exists behind each claim.

✅ Clinically validated

• Omega-3s (triglycerides), red yeast rice (LDL via natural statin) and CoQ10 (heart energy) each have RCT support for cardiovascular markers.

📊 Correlative data

• A bundle has no epidemiology of its own. Where observational evidence exists it belongs to the individual ingredients and sits on their pages — read it there rather than inferring it for the combination, which nobody has studied as a unit.

🧪 Theoretical / extrapolated benefits

• No bundle has been studied as a unit, so any claim about the combination is extrapolated from the individual components. Where two ingredients share a pathway, additivity is plausible; where they do not, expect independence. Read each component's own page for what is actually predicted of it.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Heart & Cholesterol Stack actually does

This is the one bundle in the category where two components have a genuine mechanistic reason to be superadditive, and where a third is in the box to repair a side effect the first one causes. Both facts are absent from every page that sells it.

First, the variable that decides cardiovascular risk. Every atherogenic lipoprotein particle — LDL, VLDL remnant, lipoprotein(a) — carries exactly one molecule of apolipoprotein B-100. So ApoB counts particles, and LDL cholesterol measures how much cargo those particles happen to be carrying. Atherosclerosis is driven by particles entering and being retained in the arterial intima, which makes particle number the causal quantity and LDL-C a proxy that can diverge from it.

Red yeast rice is a statin. Not statin-like — a statin. Monacolin K is chemically identical to lovastatin. It inhibits HMG-CoA reductase, hepatic cholesterol synthesis falls, SREBP-2 is cleaved and translocates to the nucleus, LDL receptor expression rises, and the liver clears more ApoB particles from plasma. That is the only arm of this bundle that touches the causal variable.

Plant sterols act on the other half of the same balance sheet, and this is the real synergy. Cholesterol reaching the enterocyte has two sources: diet and bile. Sterols and stanols compete with it for space in mixed micelles and displace it, and what does get taken up is pumped back into the lumen by the ABCG5/G8 transporter. So they cut absorption. Now put the two together: when synthesis is blocked by a statin, the body compensates by upregulating absorption — and a sterol is the specific block on that compensation. Synthesis inhibition and absorption inhibition are the two arms of cholesterol homeostasis, each one's escape route is the other's target, and that is a mechanistic argument for the combination being more than the sum. It is the best such argument in the whole Stacks category.

Omega-3 does something different and can push one number the wrong way. EPA and DHA reduce hepatic VLDL-triglyceride secretion and increase fatty acid oxidation, which is why triglycerides fall. They do not lower particle number appreciably, and DHA in particular tends to raise LDL cholesterol as triglyceride-rich particles are converted. A stack that lowers triglycerides while nudging LDL-C up is behaving exactly as the biochemistry predicts, and a reader who does not know that will read the panel as a failure.

And CoQ10 is here for a reason nobody states. The mevalonate pathway branches: HMG-CoA reductase sits upstream of both cholesterol and ubiquinone. Inhibit it with monacolin K and you lower circulating CoQ10 as a matter of chemistry. So the CoQ10 in this box is not generic heart energy — it is a repair for a depletion that the red yeast rice in the same box causes. That is an internal dependency, and it is the honest argument for its presence.

Cell, rodent, human — and where it stops

Red yeast rice in humans. In statin-intolerant patients, randomized red yeast rice lowered LDL cholesterol substantially against placebo over 24 weeks Becker 2009. The result is real and the caveat is fatal to label-reading: monacolin K content varies enormously between commercial products, including between batches of the same brand, and most products do not declare it. You are taking a statin at an undisclosed dose. That is the single most important sentence on this page.

Omega-3, at 4 grams a day, twice, with opposite answers. REDUCE-IT randomized 8,179 statin-treated patients with raised triglycerides to 4 g/day of icosapent ethyl, purified EPA, and reported a 25% relative reduction in the primary cardiovascular composite Bhatt 2019. STRENGTH randomized 13,078 comparable patients to 4 g/day of an EPA/DHA carboxylic acid mixture and was stopped for futility Nicholls 2020. Same gram dose, different molecule, different comparator oil, opposite conclusion. Anyone quoting the first trial for a fish oil capsule owes you the second.

Now the arithmetic, which is where most of this bundle fails. Both trials used 4,000 mg/day of omega-3. A cardiovascular bundle's fish oil is commonly one or two 1,000 mg capsules — and 1,000 mg is the mass of the oil, of which a standard concentration is around 300 mg EPA plus DHA. Two capsules is therefore roughly 600 mg of omega-3, about 15% of the trial dose. Not a smaller effect: an untested dose, of the formulation that failed, at a seventh of the amount that worked.

CoQ10, and the populations the evidence belongs to. Q-SYMBIO gave 300 mg/day to patients with chronic heart failure and reported fewer major adverse cardiovascular events over two years Mortensen 2014. A four-year Swedish trial combined 200 mg/day of CoQ10 with 200 micrograms of selenium in elderly citizens of a selenium-poor region and found reduced cardiovascular mortality and lower NT-proBNP Alehagen 2013. Both are heart failure or population-deficiency settings. Neither studied a person with a high LDL and a normal heart, which is who buys this box, and a bundle carrying 100 mg is at a third to a half of either dose.

Heart & Cholesterol Stack — which form, and does it matter

The fish oil label, decoded, because this is the most misread panel in the supplement aisle. 1,000 mg fish oil is the mass of oil in the capsule. The number that matters is the sum of EPA and DHA underneath it, and in an unconcentrated product that is around 300 mg. Then the ratio: REDUCE-IT used pure EPA Bhatt 2019; the mixed EPA/DHA preparation in STRENGTH did not reproduce the benefit Nicholls 2020, which is why the EPA:DHA split on the panel is a real question rather than a detail.

And the chemical form changes absorption several-fold. Most concentrated fish oils are ethyl esters, which require pancreatic lipase and are absorbed poorly on an empty stomach — taking them with a fat-containing meal can multiply exposure. Re-esterified triglyceride and free fatty acid forms absorb better without that dependency and cost more. Prescription icosapent ethyl is an ethyl ester taken with food, which is how the trial dosed it.

Red yeast rice: the only label worth buying declares monacolin K. Standardization is the whole question Becker 2009, and there is a second one — citrinin, a nephrotoxic mycotoxin produced by the same fermentation, which well-controlled products test for and cheap ones do not. European regulators have capped monacolin K per serving at a level below typical statin doses, which tells you how the product is classified where it is regulated.

Plant sterols are dosed as sterol equivalents, around 2 g/day, and they need food. The mechanism is competition inside a mixed micelle, so a sterol capsule taken away from a meal has nothing to compete with. Esterified sterols in a fat matrix were how the food products that generated the evidence delivered them.

CoQ10. Ubiquinol is the reduced form and absorbs better per milligram; ubiquinone in an oil suspension is what Q-SYMBIO used Mortensen 2014. Dry powder in a hard capsule is the form to avoid — it is close to insoluble and its milligrams are notional.

What would have to be true, and how you would know it was not

This is the stack with the best markers available, so the predictions can be numeric and dated.

1. If red yeast rice is in the box and is standardized, ApoB and LDL-C fall by 8 to 12 weeks. That is the statin mechanism on the statin timescale Becker 2009. ApoB is the one to prioritize, because it counts the particles that cause the disease. If neither moves, the most likely explanation is that the product contains little monacolin K.

2. Triglycerides fall within 4 to 8 weeks only if they were raised and only if the omega-3 dose is real. Add the EPA plus DHA milligrams across the capsules and compare with the 4,000 mg used in the trials Bhatt 2019 Nicholls 2020. Below about a gram a day, predict no meaningful triglyceride change.

3. The omega-3 index at 12 weeks, not at 4. It reports EPA and DHA as a percentage of red cell membrane fatty acids, and red cell membranes turn over across months, so this is the one test that verifies you actually absorbed what you swallowed.

4. The prediction that cuts against the stack: LDL cholesterol may go UP. A DHA-heavy fish oil converts triglyceride-rich particles and raises LDL-C, and in a bundle with no monacolin or sterol arm that is the likeliest single-number outcome of the whole purchase. Predict it, measure it, and read it as chemistry rather than betrayal.

5. Lipoprotein(a) will not move, and once in a lifetime is enough. It is genetically determined and nothing in this box touches it. It is on the list because a raised Lp(a) is the commonest unmeasured reason a person has cardiac risk they do not know about, and it is a far better use of one blood draw than anything else on this page.

6. A CMP at 12 weeks is not optional if monacolin is present. Liver enzymes are how statin therapy is monitored, and you are on one.

What nobody has tested yet

The trial with a real mechanistic hypothesis, still unrun. Synthesis inhibition and absorption inhibition target each other's escape route, so the combination has a specific reason to beat additivity. Four arms, adults with LDL-C above 130 mg/dL and no statin, roughly 60 per arm: standardized monacolin K alone; plant sterols 2 g/day alone; both; placebo. Twelve weeks, ApoB as the primary endpoint, with a pre-specified interaction test. If the combined arm beats the sum, this bundle has the only demonstrated synergy in the Stacks category. Nobody has run it, and it is an inexpensive trial with commodity ingredients.

Nobody has published an assay of monacolin K across the commercial shelf. The clinical result exists Becker 2009; the content survey that would let a buyer know what dose they are taking does not exist in any current, public form. It is analytical chemistry on twenty products and it would be the single most useful paper this category could receive.

Nobody has tested whether CoQ10 prevents monacolin-associated muscle symptoms. The CoQ10-for-statin-myalgia trials are small and inconsistent, and not one of them used red yeast rice — which is the setting where the depletion argument is strongest, because the same product causes the depletion and supplies the repair. A randomized withdrawal of the CoQ10 arm inside this bundle would answer it in eight weeks.

And nobody has run pure EPA against an EPA/DHA mixture head-to-head. The two large trials differed in molecule, in comparator oil and in population at once Bhatt 2019 Nicholls 2020, so the field cannot say which difference produced the divergent result. One trial with a common comparator would settle a question the entire fish oil market currently argues about from inference.

Heart & Cholesterol Stack — its own safety story, not its category's

Never stack red yeast rice on a prescription statin. It is the same drug class at an undeclared dose, and the combined exposure raises the risk of myopathy and, rarely, rhabdomyolysis. The same applies to combining it with a fibrate, and to taking it alongside any strong CYP3A4 inhibitor — clarithromycin, itraconazole, ritonavir, and grapefruit juice in quantity — because lovastatin is a CYP3A4 substrate and its levels rise sharply. New muscle pain, dark urine or weakness on this bundle is a same-week medical problem, not a supplement side effect to push through.

Statin contraindications apply in full. Active liver disease and pregnancy or attempted conception are the two that matter, and neither appears on a red yeast rice label because the product is not sold as a drug.

The 4-gram omega-3 risk that most pages omit: atrial fibrillation. Both large trials at that dose reported more new-onset atrial fibrillation in the omega-3 arm than in the comparator Bhatt 2019 Nicholls 2020. Add the bleeding tendency — real at high dose, additive with aspirin, clopidogrel and anticoagulants — and gram-scale fish oil becomes a decision with two sides rather than a free good.

CoQ10 and warfarin. Ubiquinone is structurally similar to vitamin K and there are reports of reduced INR on CoQ10. If you are anticoagulated, the issue is not that you cannot take it — it is that starting or stopping it needs an INR check rather than a shrug.

Plant sterols have one genuine contraindication. Sitosterolemia is a rare recessive disorder of the ABCG5/G8 transporter in which plant sterols are absorbed and accumulate, causing tendon xanthomas and premature atherosclerosis. Adding sterols there is directly harmful, and the diagnosis is usually made late.

The attribution trap this box creates. Three mechanisms started in one week means an improved panel with three candidate explanations and no way to choose. If it matters to you which bottle worked — and with a statin in the box it should — run the monacolin arm alone for 12 weeks against a baseline draw first, then add the rest.

Sources read for this page

• Becker DJ, et al. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Annals of Internal Medicine, 2009 · PMID 19528562
• Bhatt DL, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. The New England Journal of Medicine, 2019 · PMID 30415628
• Nicholls SJ, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA, 2020 · PMID 33190147
• Mortensen SA, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC: Heart Failure, 2014 · PMID 25282031
• Alehagen U, et al. Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens. International Journal of Cardiology, 2013 · PMID 22626835

How you would know if it worked

Heart & Cholesterol Stack — safety & side effects

Bloodwork to run alongside Heart & Cholesterol Stack

Baseline first, then again at 8–12 weeks.

The Basics — Start Here panel covers these in one order — 4 markers, $32.40 with the discount applied.

Check results you already have → · All 103 markers A–Z

Heart & Cholesterol Stack — frequently asked questions

What Heart & Cholesterol Stack is used for

Heart & Cholesterol Stack appears under 2 goals in the goal router.

Related Stacks & Bundles supplements

← Browse the full Supplement Vault

↑ Back to on this page